Introduction {#sec1_1}
============

TAS-102 is an oral anticancer drug containing trifluridine and tipiracil hydrochloride \[[@B1]\]. Trifluridine is incorporated into DNA, and this process might result in its anticancer effects. Tipiracil hydrochloride assists in maintaining the blood concentrations of trifluridine by inhibiting the thymidine phosphorylase that degrades trifluridine. In the global phase III RECOURSE trial, patients who were given TAS-102 demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) compared with those given a placebo (hazard ratio, 0.68 and 0.48 for OS and PFS, respectively; both *p* \< 0.0001) \[[@B2]\]. Grade 3 or higher adverse events frequently observed in the TAS-102 arm included neutropenia (38%) \[[@B2]\]. Neutropenia is an important adverse event that affects the continuation of chemotherapy. Therefore, overcoming neutropenia may be considered to lead to improved survival. In this report, we present a case in which neutropenia could be avoided by changing to a simple administration method of TAS-102.

Case Report {#sec1_2}
===========

A 62-year-old woman was referred to our hospital with stage IV descending colon cancer. Colonoscopy revealed a nearly obstructing tumor in the descending colon. Abdominal CT revealed multiple hepatic metastases. The patient underwent a left hemicolectomy (open surgery). KRAS codon 12 showed TGT mutation. We started XELOX + bevacizumab therapy (BV \[7.5 mg/kg\] and oxaliplatin \[130 mg/m^2^\] on day 1 plus capecitabine \[1,000 mg/m^2^\] twice daily on days 1--14, every 3 weeks) as a first-line treatment \[[@B3]\] and then started IRIS + bevacizumab therapy (BV \[7.5 mg/kg\] and irinotecan \[150 mg/m^2^\] on day 1 plus S-1 \[80 mg/m^2^\] twice daily on days 1--14, every 3 weeks) as a second-line treatment \[[@B4]\]. Prior to chemotherapy, the renal, hepatic, and bone marrow functions were almost normal. TAS-102 (35 mg/m^2^) was administered as a third-line treatment twice daily, after breakfast and dinner, for 5 days a week with 2 days of rest for 2 weeks, followed by a 14-day rest period (Fig. [1a](#f1){ref-type="fig"}). The results of routine blood analysis after 1 cycle revealed that the white blood cell (WBC) count was 1,200/μL (normal range, 3,300--8,600/μL) and the absolute neutrophil count was 330/μL (normal range, 50--70% of WBC). Chemotherapy was restarted as neutrophils normalized after 2 weeks' withdrawal. The dose interval was modified without changing the dose intensity. TAS-102 (35 mg/m^2^) was administered twice daily, after breakfast and dinner, for 5 days a week with 9 days of rest for 2 weeks (Fig. [1b](#f1){ref-type="fig"}). The analysis after the second cycle revealed that the WBC count was 3,100/μL and the absolute neutrophil count was 2,083/μL (Table [1](#T1){ref-type="table"}). The analysis after the third cycle revealed that the WBC count was 2,500/μL and the absolute neutrophil count was 1,415/μL.

Discussion {#sec1_3}
==========

Neutropenia is the most common cause of chemotherapy dose reduction and delay \[[@B5]\]. The frequency of neutropenia differs according to the chemotherapy regimen even if the same anticancer drug is administered \[[@B6], [@B7]\]. Grade 3--4 hematologic toxicity, mainly neutropenia, was approximately seven times more frequent in the 5-FU bolus arm, whereas hand-foot syndrome was approximately two times more frequent in the 5-FU continuous infusion arm \[[@B8]\]. Prolonged infusion may expose a relatively larger proportion of tumor cells to 5-FU \[[@B6]\]. Moreover, extending the time of infusion is an attractive option for tumors with a relatively slow doubling time, such as colorectal cancers \[[@B9], [@B10]\]. It has been suggested that the mechanisms of resistance to 5-FU depend on the modality of its administration. Bolus administration of 5-FU inhibits RNA synthesis, whereas continuous infusion may be more cytotoxic via the inhibition of thymidilate synthase \[[@B11]\]. Delivering 5-FU by continuous infusion rather than by bolus intravenous infusion permits the delivery of higher drug doses and changes the limiting toxicity from myelosuppression to stomatitis and hand-foot syndrome. Examining the findings revealed that adverse events also differ when administration methods are different. Although details on TAS-102 are unknown, our outcome suggests that neutropenia caused by TAS-102 may be associated with the dosing interval.

Patients who develop neutropenia experience an increased risk of serious infections and often require hospitalization \[[@B12]\]. Therefore, the prevention and management of neutropenia is an important issue in chemotherapy of CRC. A modified regimen may reduce the risk of infection and hospitalization. However, since the anticancer effect is unknown, further study is necessary.

To our best knowledge, this is the first report in which neutropenia could be prevented by changing to a simple administration method of TAS-102. The work is original. However, given the low number of patients considered, it is not possible to come to any well-defined conclusion. Based on the present case, several changes may be necessary, including how best to individualize dosing schedules.
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White blood cells (WBC) and neutrophils (/μL) after chemotherapy

              Regimen   WBC     Neutrophil
  ----------- --------- ------- ------------
  1st cycle   A         1,200   330
  2nd cycle   B         3,100   2,083
  3rd cycle   B         2,500   1,415
